|
|
|
|
| TRADING CENTER |
51.00+0.62 / +1.23%
Genzyme Corporation (NASDAQ GS:GENZ)
Prev. Close:
50.38
Open:
50.82
High:
51.09
Low:
50.59
Volume:
1,551,090
Volume Avg.:
3,460,800
52wk Range:
47.09 - 73.75
Market Cap (mil):
13,534.53
P/E Ratio:
28.98
Dividend Yield:
N/A
| Shire Drug Seeks EU Nod - Analyst Blog - Zacks.com | |
| InvestorSoup.com Issues Technical Trading Outlook for ARCA biopharma Inc. - GlobeNewswire | |
| Top Takes From RealMoney - at TheStreet.com | |
| Wall Street's 10 Favorite Stocks Right Now - MotleyFool.com | |
| Biotech Stock Mailbag: FDA Playbook - at TheStreet.com | |
| Now's a Great Time to Invest -- So Don't Blow It Like This - MotleyFool.com | |
| This Stock Is a Train Wreck - MotleyFool.com | |
| Genzyme's Problems Continue - Analyst Blog - Zacks.com | |
| Genzyme: Analysts' Upgrades, Downgrades - at TheStreet.com | |
| Zacks #5 Rank Additions for Thursday - Zacks Tale of the Tape - Zacks.com | |
| Genzyme's bad year gets worse: Experimental kidney drug a no-go - DailyFinance | |
| Drug Lowers Cholesterol; Stock Follows - MotleyFool.com | |
| Genzyme negative news continues; stops drug trial - Reuters | |
| Another Genzyme Drug Goes Kaboom: BioBuzz - at TheStreet.com | |
| Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder - Business Wire |
| Last trade | Change/%change | P/E ratio | ||
|---|---|---|---|---|
| AMGN | Amgen Inc | 57.29 | 0.49 / 0.86% | 10.95 |
| GILD | Gilead Sciences Inc | 46.90 | -0.06 / -0.13% | 18.11 |
| CELG | Celgene Corporation | 55.59 | 0.22 / 0.40% | 66.98 |
Short Interest Date:
Oct 30 2009
Short Interest Shares:
5,118,715
Short Interest Ratio:
1.8
Float:
269,399,467
Short Interest as a % of Float:
1.9%
Average Daily Volume:
3,648,300
Outstanding Shares:
265,382,892
Genzyme focuses on developing, manufacturing, and marketing products to treat genetic disorders and other chronic debilitating diseases. The company's broad product and service portfolio addresses patients on a global scale, ranging from rare disease therapeutics to cancer diagnostics. Acquisitions ... (more)
| 2008 Revenue: | $4.6 B | Headquarters: Cambridge, MA |
| Employees: | 11,000 | CEO: Henri A. Termeer |
| Net Income: | $421.1 M | Industry: Biotechnology |
| Market Cap: | $13.3 B | Website: www.genzyme.com |
| Symbol | Price | Change/%Change | Prev. close | High | Low | Last Update | More Info |
|---|---|---|---|---|---|---|---|
| GENZ | 51.00 | +0.62 / +1.23% | 50.38 | 51.09 | 50.59 | Profile Chart News |
© 2009 Cable News Network. A Time Warner Company. All Rights Reserved.
Terms under which this service is provided to you. Privacy Policy
Live Quotes automatically refresh, but individual equities are delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET.
* : Time reflects local markets trading time. † - Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Disclaimer
* : Time reflects local markets trading time. † - Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Disclaimer
| Copyright © 2009 BigCharts.com Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc. Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use. Intraday data is at least 20-minutes delayed. All times are ET. Historical, current end-of-day data, and splits data provided by Interactive Data Pricing and Reference Data. Fundamental data provided by Morningstar, Inc.. SEC Filings data provided by Edgar Online Inc.. Earnings data provided by FactSet CallStreet, LLC. |
